Platform for CML-patients, caregivers and informal care.
The quality of care for patients with chronic myeloid leukaemia depends on the hospital or GP a patient goes to. The care that is given doesn’t always follow the guidelines, the number of check-ups each year differs and due to the side effects of the heavy medication the adherence is sometimes lower than the 100% that is necessary for good outcomes.
How can we improve the quality of life and quality of care for patients with chronic myeloid leukaemia?
With HereIsMyData we’re building on a concept that breaks down the silos of information in health and care. Using a single point of access for all your health related data where you decide who get’s access to your data and who doesn’t.
What did we do?
REshape facilitated a ’30 day project’ with the department of haematology at Radboudumc and the patient organisation ‘Hematon’. Before we started the project, we started listening. Listening to the people with CML at their homes, to understand which problems occur in this group and to learn more about the needs that are specific for this patient group. Based on this information REshape, the department of haematology and Hematon developed the concept-solution.
You can watch the Dutch video with a short introduction about the platform below.
Chronic Myeloid Leukaemia (CML) is a rare disease. Each year approximately 165 persons get diagnosed with CML. There are about 1.800 patients with CML in the Netherlands. The total number of patients is growing since the medication has greatly improved in the year 2000.
Prof. Dr. Nicole BlijlevensInternist Haematologist
“CMyLife improves the quality of care for patients with CML. By allowing people to take control of their own care-process they can better shape their live with the disease in a way that fits their personal situation.”
Barend HeerenProgrammanager HereIsMyData at Radboudumc
“With CMyLife we’re able to empower patients by giving them the tools they need to understand and check if they receive the right care and to manage their own side-effects.”